hematopoietic stem cell transplantation

(redirected from HSC transplant)

hematopoietic stem cell transplantation

Hematology A therapy in which defective hematopoietic cells are replaced with normal BM cells after chemotherapy and/or RT Indications AML, breast CA, CML, germ cell tumors, lymphoma, myelodysplastic syndrome, myeloma, neuroblastoma, ovarian CA, Wilms' tumor; nonmalignant lesions–congenital metabolic diseases, SCID
References in periodicals archive ?
Of these, 13 (93%) were asymptomatic: 1 kidney, 1 heart, and 11 HSC transplant recipients (Table 1).
([paragraph]) Group in which HSC transplant patients are most at risk for toxoplasmosis.
Therefore, to treat acquired SAA, HSC transplant from matched sibling donor is a matter of choice, which in some cases is satisfactorily effective [15].
Hence, animal models have been developed to assess the response of MSCs in acquired AA as well as the hematologic cell amelioration [22-24] to find conditions to improve HSC transplant regimens or even to evaluate its own effect to reverse BMF and consequently to enhance survival rates of the patients.
Nevertheless, the success of HSC transplant is limited due to late complications, such as graft rejection and relapse due to resurgent autoimmune attack, and more often due to development of GVHD [15, 37], whereas lack of response, relapse, and clonal evolution limit the success of IS drugs [38].
As they wait in the protected confines of a hospital, patients, who undergo HSC transplants, receive blood tests every day to gauge successful engraftment, searching for the presence of immune cells called neutrophils, had explained Kirsten M.
Each of these patients had successful engraftment, reflected in blood tests two to four weeks after their HSC transplants. However, the results of the imaging exams revealed a far more complicated and robust story.
Leukemia patients have been successfully treated using HSC transplants, but medical experts believe blood stem cells have the potential to be used more widely.
Cochlear regeneration was only observed in animal groups that received HSC transplants. Researchers used sensitive tracing methods to determine if the transplanted cells were capable of migrating to the cochlea and evaluated whether the cells could contribute to regenerating neurons and sensory tissue in the cochlea.
As the company begins administering CLT-001 to patients in 2006 in clinical studies, it expects that CLT-001 may enable more widespread use of HSC transplants in sickle cell disease and other genetic blood disorders through a reduced risk of GVHD.
"Our next step is to examine single HSC transplants into injured animals," she said.